Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LNTH NASDAQ:MIRM NASDAQ:NBTX NASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNTHLantheus$108.96-1.8%$96.93$47.25▼$111.86$7.09B-0.03969,016 shs909,290 shsMIRMMirum Pharmaceuticals$120.46+2.9%$101.44$47.89▼$125.39$7.35B0.5938,695 shs1.01 million shsNBTXNanobiotix$39.48+4.7%$38.67$4.73▼$57.14$2.00B0.7462,869 shs77,270 shsPTCTPTC Therapeutics$81.35-0.3%$72.95$43.17▼$87.50$6.77B0.561.43 million shs1.22 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNTHLantheus+1.24%+4.63%+11.72%+46.55%+35.52%MIRMMirum Pharmaceuticals-4.78%+5.33%+15.39%+23.78%+130.14%NBTXNanobiotix+4.84%+3.01%-6.68%+10.65%+697.04%PTCTPTC Therapeutics0.00%-0.68%+10.45%+18.65%+67.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLNTHLantheus$108.96-1.8%$96.93$47.25▼$111.86$7.09B-0.03969,016 shs909,290 shsMIRMMirum Pharmaceuticals$120.46+2.9%$101.44$47.89▼$125.39$7.35B0.5938,695 shs1.01 million shsNBTXNanobiotix$39.48+4.7%$38.67$4.73▼$57.14$2.00B0.7462,869 shs77,270 shsPTCTPTC Therapeutics$81.35-0.3%$72.95$43.17▼$87.50$6.77B0.561.43 million shs1.22 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLNTHLantheus+1.24%+4.63%+11.72%+46.55%+35.52%MIRMMirum Pharmaceuticals-4.78%+5.33%+15.39%+23.78%+130.14%NBTXNanobiotix+4.84%+3.01%-6.68%+10.65%+697.04%PTCTPTC Therapeutics0.00%-0.68%+10.45%+18.65%+67.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLNTHLantheus 2.73Moderate Buy$101.86-6.52% DownsideMIRMMirum Pharmaceuticals 2.93Moderate Buy$139.8016.06% UpsideNBTXNanobiotix 2.50Moderate Buy$37.33-5.44% DownsidePTCTPTC Therapeutics 2.71Moderate Buy$91.3612.30% UpsideCurrent Analyst Ratings BreakdownLatest NBTX, MIRM, LNTH, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$115.006/23/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)6/15/2026MIRMMirum Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/15/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/15/2026MIRMMirum Pharmaceuticals CLSASubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$146.006/15/2026MIRMMirum Pharmaceuticals Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$140.00 ➝ $146.006/11/2026MIRMMirum Pharmaceuticals Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$140.00 ➝ $150.006/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.006/8/2026MIRMMirum Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Sell (D)6/4/2026NBTXNanobiotix Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$37.00 ➝ $46.006/2/2026MIRMMirum Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform ➝ Buy$145.00(Data available from 7/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLNTHLantheus$1.54B4.60$6.35 per share17.16$16.43 per share6.63MIRMMirum Pharmaceuticals$521.31M14.09$0.05 per share2,412.75$6.12 per share19.68NBTXNanobiotix$36.87M54.20N/AN/A($1.97) per share-20.04PTCTPTC Therapeutics$1.73B3.90$8.76 per share9.29($2.56) per share-31.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLNTHLantheus$233.56M$4.1526.2620.25N/A18.05%29.32%15.00%8/5/2026 (Estimated)MIRMMirum Pharmaceuticals-$23.36M-$13.61N/A523.74N/A-140.24%-11.28%-3.84%7/30/2026 (Estimated)NBTXNanobiotix-$27.11MN/AN/A62.67N/AN/AN/AN/AN/APTCTPTC Therapeutics$682.64M-$2.33N/A38.553.75-22.58%-362.45%-6.76%8/6/2026 (Estimated)Latest NBTX, MIRM, LNTH, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/6/2026Q1 2026MIRMMirum Pharmaceuticals-$0.75-$13.43-$12.68-$13.43$148.21 million$159.88 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLNTHLantheusN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLNTHLantheus0.472.832.64MIRMMirum Pharmaceuticals1.282.091.99NBTXNanobiotixN/A1.091.09PTCTPTC TherapeuticsN/A2.442.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLNTHLantheus99.06%MIRMMirum PharmaceuticalsN/ANBTXNanobiotix38.81%PTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipLNTHLantheus1.70%MIRMMirum Pharmaceuticals8.32%NBTXNanobiotix3.45%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableMIRMMirum Pharmaceuticals14060.98 million55.91 millionOptionableNBTXNanobiotix10050.62 million48.87 millionNot OptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableNBTX, MIRM, LNTH, and PTCT HeadlinesRecent News About These CompaniesNeil Gregory Almstead Sells 8,130 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJuly 1 at 4:51 AM | insidertrades.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells $693,163.80 in StockJune 30 at 7:06 PM | marketbeat.comPictet Asset Management Holding SA Has $80.06 Million Stock Holdings in PTC Therapeutics, Inc. $PTCTJune 30 at 4:55 AM | marketbeat.comLouisiana State Employees Retirement System Takes Position in PTC Therapeutics, Inc. $PTCTJune 30 at 4:47 AM | marketbeat.comOP Asset Management Ltd Acquires Shares of 33,602 PTC Therapeutics, Inc. $PTCTJune 28 at 4:39 AM | marketbeat.comNeil Gregory Almstead Sells 20,960 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 28 at 4:37 AM | americanbankingnews.comNeil Gregory Almstead Sells 5,323 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 27, 2026 | insidertrades.comPTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 5,323 SharesJune 26, 2026 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Insider Sells 20,960 Shares of StockJune 26, 2026 | marketbeat.comNeil Gregory Almstead Sells 23,749 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 26, 2026 | americanbankingnews.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells $1,921,294.10 in StockJune 25, 2026 | insidertrades.comPTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 10,462 SharesJune 23, 2026 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) CAO Christine Marie Utter Sells 19,686 SharesJune 23, 2026 | americanbankingnews.comMark Elliott Boulding Sells 10,462 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 23, 2026 | insidertrades.comPTC Therapeutics, Inc. $PTCT Shares Sold by BI Asset Management Fondsmaeglerselskab A SJune 23, 2026 | marketbeat.comMark Elliott Boulding Sells 10,462 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 22, 2026 | marketbeat.comPTC Therapeutics, Inc. $PTCT Shares Sold by Rockefeller Capital Management L.P.June 22, 2026 | marketbeat.comPacer Advisors Inc. Has $17.90 Million Position in PTC Therapeutics, Inc. $PTCTJune 21, 2026 | marketbeat.comPTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?June 18, 2026 | zacks.comIshara Investments LP Invests $2.74 Million in PTC Therapeutics, Inc. $PTCTJune 18, 2026 | marketbeat.comArmistice Capital LLC Sells 475,403 Shares of PTC Therapeutics, Inc. $PTCTJune 18, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBTX, MIRM, LNTH, and PTCT Company DescriptionsLantheus NASDAQ:LNTH$108.96 -1.98 (-1.78%) Closing price 04:00 PM EasternExtended Trading$108.94 -0.02 (-0.01%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$120.46 +3.39 (+2.90%) Closing price 04:00 PM EasternExtended Trading$120.49 +0.03 (+0.02%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.Nanobiotix NASDAQ:NBTX$39.48 +1.78 (+4.72%) Closing price 04:00 PM EasternExtended Trading$39.65 +0.17 (+0.42%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.PTC Therapeutics NASDAQ:PTCT$81.35 -0.22 (-0.27%) Closing price 04:00 PM EasternExtended Trading$81.35 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks AirJoule Unveils Prime System, Clearing Path to Commercialization Comcast’s NBCUniversal Split Puts Broadband Back in Focus Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
